To page body
university of tampere: faculty of medicine and life sciences: research: jorma isola - cancer biology:
Lääketieteen ja biotieteiden tiedekuntaUniversity of TampereLääketieteen ja biotieteiden tiedekunta
Jorma Isola - Cancer Biology

Previous publications

Pasanen A, Tuomi T, Isola J, Staff S, Bützow R, Loukovaara M
L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Int J Gynecol Cancer ;26(8)1465-71, 2016

She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
BMC Cancer ;2016

Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H
Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Breast Cancer Res Treat ;157(3)437-46, 2016

Luhtala S, Staff S, Barok M, Tanner M, Isola J
Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer.
Appl Immunohistochem Mol Morphol ;2016

Luhtala S, Staff S, Tanner M, Isola J
Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Tumour Biol ;37(7)9813-23, 2016

Helin HO, Tuominen VJ, Ylinen O, Helin HJ, Isola J
Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Virchows Arch ;468(2)191-8, 2016

Tolonen T, Näpänkangas J, Isola J
[Clinical pathology on the verge of virtual microscopy].
Duodecim 2015 ;131(21)1981-7

Holmström O, Linder N, Lundin M, Moilanen H, Suutala A, Turkki R, Joensuu H, Isola J, Diwan V, Lundin J
Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-Scanner.
PLoS One 2015 ;10(12)e0144688

Laiho JE, Oikarinen S, Oikarinen M, Larsson PG, Stone VM, Hober D, Oberste S, Flodström-Tullberg M, Isola J, Hyöty H
Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology.
J Clin Virol 2015 ;69165-71

Tolonen TT, Isola J, Kaipia A, Riikonen J, Koivusalo L, Huovinen S, Laurila M, Porre S, Tirkkonen M, Kujala P
Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study.
BMC Clin Pathol 2015 ;154

Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J
Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
Genes Chromosomes Cancer 2015 ;54(5)276-87

Vassilev B, Sihto H, Li S, Hölttä-Vuori M, Ilola J, Lundin J, Isola J, Kellokumpu-Lehtinen PL, Joensuu H, Ikonen E
Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.
Am J Pathol 2015 ;185(4)987-1000

Barok M, Joensuu H, Isola J
Trastuzumab emtansine: mechanisms of action and drug resistance.
Breast Cancer Res 2014 ;16(2)209

Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J
Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Int J Gynecol Pathol 2014 ;33(3)309-16

Saarelainen SK, Staff S, Peltonen N, Lehtimäki T, Isola J, Kujala PM, Vuento MH, Mäenpää JU
Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.
Tumour Biol 2014 ;35(5)4651-7

Falck AK, Bendahl PO, Ingvar C, Isola J, Jönsson PE, Lindblom P, Lövgren K, Rennstam K, Fernö M, Rydén L
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
BMC Cancer 2012 ;12403

Remes SM, Tuominen VJ, Helin H, Isola J, Arola J
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.
Am J Surg Pathol 2012 ;36(9)1359-63

Partanen L, Staaf J, Tanner M, Tuominen VJ, Borg Å, Isola J
Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Genes Chromosomes Cancer 2012 ;51(9)832-40

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T
Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
J Pathol 2012 ;227(3)336-45

Tuominen VJ, Tolonen TT, Isola J
ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry.
Histopathology 2012 ;60(5)758-67

Lehtimäki T, Lundin M, Linder N, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H, Lundin J
Long-term prognosis of breast cancer detected by mammography screening or other methods.
Breast Cancer Res 2011 ;13(6)R134

Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S
Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins.
PLoS One 2011 ;6(11)e27152

Tolonen TT, Kujala PM, Tammela TL, Tuominen VJ, Isola JJ, Visakorpi T
Overall and worst gleason scores are equally good predictors of prostate cancer progression.
BMC Urol 2011 ;1121

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M,
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Lancet Oncol 2011 ;12(12)1134-42

Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
Breast Cancer Res 2011 ;13(5)R87

Tothova V, Isola J, Parkkila S, Kopacek J, Pastorek J, Pastorekova S, Gibadulinova A
Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein.
J Cell Biochem 2011 ;112(11)3373-84

Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
BJU Int 2011 ;108(9)1430-8

Barok M, Tanner M, Köninki K, Isola J
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Breast Cancer Res 2011 ;13(2)R46

Tolonen TT, Kujala PM, Laurila M, Tirkkonen M, Ilvesaro J, Tuominen VJ, Tammela TL, Isola J
Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies.
Hum Pathol 2011 ;42(11)1635-42

Barok M, Tanner M, Köninki K, Isola J
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
Cancer Lett 2011 ;306(2)171-9

Junttila TT, Tanner M, Isola J
[Targeted cytotoxic drugs emerging for cancer therapy].
Duodecim 2011 ;127(4)343-9

Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.
BMC Clin Pathol 2011 ;113

Lassus H, Staff S, Leminen A, Isola J, Butzow R
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
Gynecol Oncol 2011 ;120(1)11-7

Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, Isola J
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.
Breast Cancer Res 2010 ;12(4)R56

Saarilahti K, Bono P, Kajanti M, Bäck L, Leivo I, Joensuu T, Isola J, Mäkitie AA
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer.
J Otolaryngol Head Neck Surg 2010 ;39(3)269-76

Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, Hemmilä P, Ilvesaro J, Isola J
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Cancer Lett 2010 ;294(2)211-9

Parkkila S, Lasota J, Fletcher JA, Ou WB, Kivelä AJ, Nuorva K, Parkkila AK, Ollikainen J, Sly WS, Waheed A, Pastorekova S, Pastorek J, Isola J, Miettinen M
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors.
Mod Pathol 2010 ;23(5)743-50

Staff S, Isola J, Jumppanen M, Tanner M
Aurora-A gene is frequently amplified in basal-like breast cancer.
Oncol Rep 2010 ;23(2)307-12

Joensuu G, Joensuu T, Nokisalmi P, Reddy C, Isola J, Ruutu M, Kouri M, Kupelian PA, Collan J, Pesonen S, Hemminki A
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.
Int J Radiat Oncol Biol Phys 2010 ;78(1)42-9

Tuominen VJ, Isola J
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol.
J Digit Imaging 2010 ;23(4)454-62

Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
J Clin Oncol 2009 ;27(34)5685-92

Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J
CIP2A is associated with human breast cancer aggressivity.
Clin Cancer Res 2009 ;15(16)5092-100

Gong Y, Sweet W, Duh YJ, Greenfield L, Tarco E, Trivedi S, Symmans WF, Isola J, Sneige N
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.
Am J Clin Pathol 2009 ;132(2)228-36

Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Cancer Res 2009 ;69(15)6299-306

Köninki K, Tanner M, Auvinen A, Isola J
HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.
Breast Cancer Res 2009 ;11(3)R37

Juuti-Uusitalo K, Lindfors K, Mäki M, Patrikainen M, Isola J, Kaukinen K
Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after in vitro gliadin insult.
Scand J Gastroenterol 2009 ;44(7)820-5

Gong Y, Sweet W, Duh YJ, Greenfield L, Fang Y, Zhao J, Tarco E, Symmans WF, Isola J, Sneige N
Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Am J Clin Pathol 2009 ;131(4)490-7

Korja M, Jokilammi A, Salmi TT, Kalimo H, Pelliniemi TT, Isola J, Rantala I, Haapasalo H, Finne J
Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma.
BMC Cancer 2009 ;957

Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Luukkaala T, Määttänen L, Ruutu M, Ala-Opas M, Mildh M, Martikainen P
Biological aggressiveness of prostate cancer in the Finnish screening trial.
Int J Cancer 2009 ;124(3)547-52

Mäenpää J, Tanner M, Isola J
Analyzing toposimerase II-alpha and HER-2/neu co-amplification seems to be of limited value in epithelial ovarian cancer.
Acta Oncol 2009 ;48(4)617-9

Tuominen VJ, Isola J
The application of JPEG2000 in virtual microscopy.
J Digit Imaging 2009 ;22(3)250-8

Linder E, Lundin M, Thors C, Lebbad M, Winiecka-Krusnell J, Helin H, Leiva B, Isola J, Lundin J
Web-based virtual microscopy for parasitology: a novel tool for education and quality assurance.
PLoS Negl Trop Dis 2008 ;2(10)e315

Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, Sailas L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H
Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
Clin Cancer Res 2008 ;14(13)4103-10

Parkkila S, Pan PW, Ward A, Gibadulinova A, Oveckova I, Pastorekova S, Pastorek J, Martinez AR, Helin HO, Isola J
The calcium-binding protein S100P in normal and malignant human tissues.
BMC Clin Pathol 2008 ;82

Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.
Cancer Lett 2008 ;260(1-2)198-208

Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
Nat Genet 2008 ;40(1)102-7

Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
Int J Cancer 2008 ;122(3)595-602

Dihge L, Bendahl PO, Grabau D, Isola J, Lövgren K, Rydén L, Fernö M
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Breast Cancer Res Treat 2008 ;109(2)255-62

Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Eur J Cancer 2007 ;43(16)2423-33

Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H, Croce CM, Elenius K
Association of Wwox with ErbB4 in breast cancer.
Cancer Res 2007 ;67(19)9330-6

Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Mol Cancer Ther 2007 ;6(7)2065-72

Sand J, Tani T, Laukkarinen J, Välikoski A, Isola J, Nordback I
Ultra thin needle histology may have impact in diagnosing chronic pancreatitis.
Scand J Gastroenterol 2007 ;42(4)508-12

Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Proc Natl Acad Sci U S A 2007 ;104(18)7564-9

Laukkarinen JM, Sand JA, Chow P, Juuti H, Kellomäki M, Kärkkäinen P, Isola J, Yu S, Somanesan S, Kee I, Song IC, Ng TH, Nordback IH
A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: an 18-month follow-up in a large animal model.
J Gastrointest Surg 2007 ;11(6)750-7

Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Clin Cancer Res 2007 ;13(7)1987-94

Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Breast Cancer Res 2007 ;9(1)R16

Rennstam K, Jönsson G, Tanner M, Bendahl PO, Staaf J, Kapanen AI, Karhu R, Baldetorp B, Borg A, Isola J
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.
Cancer Genet Cytogenet 2007 ;172(2)95-106

Puputti M, Tynninen O, Sihto H, Blom T, Mäenpää H, Isola J, Paetau A, Joensuu H, Nupponen NN
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Mol Cancer Res 2006 ;4(12)927-34

Lundin J, Lehtimäki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H
Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series.
Eur J Cancer 2006 ;42(18)3228-35

Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
Clin Cancer Res 2006 ;12(14 Pt 1)4185-91

Sihto H, Franssila K, Tanner M, Vasama-Nolvi C, Sarlomo-Rikala M, Nupponen NN, Joensuu H, Isola J
Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours.
Scand J Gastroenterol 2006 ;41(7)805-11

Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H
Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression.
J Neurooncol 2006 ;80(1)1-7

, Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
J Clin Oncol 2006 ;24(16)2428-36

Puputti M, Sihto H, Isola J, Butzow R, Joensuu H, Nupponen NN
Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer.
Cancer Genet Cytogenet 2006 ;167(1)32-8

Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma.
J Mol Med 2006 ;84(8)671-81

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J,
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
N Engl J Med 2006 ;354(8)809-20

Helin HO, Lundin ME, Laakso M, Lundin J, Helin HJ, Isola J
Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry.
J Urol 2006 ;175(2)495-9

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Immunol Lett 2006 ;104(1-2)146-55

Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J, Egeblad M, Elenius K
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.
Mol Biol Cell 2006 ;17(1)67-79

Korja M, Finne J, Salmi TT, Kalimo H, Karikoski R, Tanner M, Isola J, Haapasalo H
Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas.
Mod Pathol 2005 ;18(12)1599-605

Mocanu MM, Fazekas Z, Petrás M, Nagy P, Sebestyén Z, Isola J, Tímár J, Park JW, Vereb G, Szöllosi J
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
Cancer Lett 2005 ;227(2)201-12

Altundag K, Altundag O, Morandi P, Ozcakar B, Boruban C, Tanner M, Isola J
The role of insulin-like growth factor-I receptor in the development of Herceptin resistance.
Mol Cancer Ther 2005 ;4(7)1136; author reply 1136

Laakso M, Loman N, Borg A, Isola J
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Mod Pathol 2005 ;18(10)1321-8

Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H
Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
Clin Cancer Res 2005 ;11(12)4372-81

Helin H, Lundin M, Lundin J, Martikainen P, Tammela T, Helin H, van der Kwast T, Isola J
Web-based virtual microscopy in teaching and standardizing Gleason grading.
Hum Pathol 2005 ;36(4)381-6

Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu H, Isola J, Elenius K
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.
Cancer Res 2005 ;65(4)1384-93

Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Cancer Res 2005 ;65(2)473-82

Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer.
Mol Cancer Ther 2004 ;3(12)1585-92

Lundin J, Lundin M, Isola J, Joensuu H
Validation of a Web-based prognostic system for breast cancer.
Stud Health Technol Inform 2004 ;107(Pt 1)237-40

Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J
Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
JAMA 2004 ;292(9)1064-73

Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
Clin Cancer Res 2004 ;10(14)4793-8

Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, Isola J, Yatabe Y, Nakachi K, Boecker W, Brandt B
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study.
J Pathol 2004 ;203(1)545-50

Isola J, Tanner M
Chromogenic in situ hybridization in tumor pathology.
Methods Mol Med 2004 ;97133-44

Raitanen M, Worsham MJ, Lakkala T, Carey TE, Van Dyke DL, Grénman R, Klemi P, Rantanen V, Isola J, Grénman S
Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry.
Gynecol Oncol 2004 ;93(1)155-63

Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J, Butzow R
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma.
Gynecol Oncol 2004 ;92(1)31-9

Lehtonen R, Kiuru M, Vanharanta S, Sjöberg J, Aaltonen LM, Aittomäki K, Arola J, Butzow R, Eng C, Husgafvel-Pursiainen K, Isola J, Järvinen H, Koivisto P, Mecklin JP, Peltomäki P, Salovaara R, Wasenius VM, Karhu A, Launonen V, Nupponen NN, Aaltonen LA
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.
Am J Pathol 2004 ;164(1)17-22

Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.
Cancer Res 2003 ;63(24)8861-8

Lundin J, Lundin M, Isola J, Joensuu H
Evaluation of a web-based system for survival estimation in breast cancer.
Stud Health Technol Inform 2003 ;95788-93

Junttila TT, Laato M, Vahlberg T, Söderström KO, Visakorpi T, Isola J, Elenius K
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.
Clin Cancer Res 2003 ;9(14)5346-57

Di Leo A, Isola J
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Clin Breast Cancer 2003 ;4(3)179-86

Zhang F, Lundin M, Ristimäki A, Heikkilä P, Lundin J, Isola J, Joensuu H, Laiho M
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas.
Cancer Res 2003 ;63(16)5005-10

Staff S, Isola J, Tanner M
Haplo-insufficiency of BRCA1 in sporadic breast cancer.
Cancer Res 2003 ;63(16)4978-83

Sallinen SL, Sallinen P, Ahlstedt-Soini M, Haapasalo H, Helin H, Isola J, Karhu R
Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines.
Cancer Genet Cytogenet 2003 ;144(1)52-60

Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T
Expression of ERalpha and ERbeta in prostate cancer.
Prostate 2003 ;55(3)180-6

Johannsson OT, Staff S, Vallon-Christersson J, Kytöla S, Gudjonsson T, Rennstam K, Hedenfalk IA, Adeyinka A, Kjellén E, Wennerberg J, Baldetorp B, Petersen OW, Olsson H, Oredsson S, Isola J, Borg A
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier.
Lab Invest 2003 ;83(3)387-96

Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Clin Cancer Res 2003 ;9(3)923-30

Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G, van de Vijver M
Current perspectives on HER2 testing: a review of national testing guidelines.
Mod Pathol 2003 ;16(2)173-82

Lundin J, Lundin M, Isola J, Joensuu H
A web-based system for individualised survival estimation in breast cancer.
BMJ 2003 ;326(7379)29

Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W, Buerger H
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.
Lab Invest 2002 ;82(11)1525-33

Gancberg D, Järvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.
Breast Cancer Res Treat 2002 ;74(2)113-20

Kiuru M, Lehtonen R, Arola J, Salovaara R, Järvinen H, Aittomäki K, Sjöberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, Launonen V, Karhu A, Aaltonen LA
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families.
Cancer Res 2002 ;62(16)4554-7

Karhu R, Vilpo L, Isola J, Knuutila S, Vilpo J
Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation.
Genes Chromosomes Cancer 2002 ;34(3)345-8

Kytölä S, Nord B, Elder EE, Carling T, Kjellman M, Cedermark B, Juhlin C, Höög A, Isola J, Larsson C
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.
Genes Chromosomes Cancer 2002 ;34(3)325-32

Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Clin Cancer Res 2002 ;8(5)1107-16

Paunu N, Pukkala E, Laippala P, Sankila R, Isola J, Miettinen H, Simola KO, Helén P, Helin H, Haapasalo H
Cancer incidence in families with multiple glioma patients.
Int J Cancer 2002 ;97(6)819-22

Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Cancer Res 2002 ;62(3)632-5

Savinainen KJ, Saramäki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, Visakorpi T
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.
Am J Pathol 2002 ;160(1)339-45

Akervall J, Borg A, Dictor M, Jin C, Jin Y, Tanner M, Isola J, Mertens F, Wennerberg J
Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
Int J Oncol 2002 ;20(1)45-52

Faculty of Medicine and Life Sciences
Arvo Ylpön katu 34
33520 Tampere, Finland
Maintained by:
Last update: 12.8.2014 13.26 Muokkaa

University of Tampere
+358 3 355 111

FINEEC Audited HR Excellence in Research

Cooperation and Services
About Us

Research & Study

Career Services
Finnish Social Science Data Archive
Centre for International Education
IT services
Language Centre
Language Services
Registrar's Office
Sports Activities
» more

Teaching schedules
Curricula guides
Student's Desktop

Andor search
Renew your loans
UTA intranet
Office 365 webmail
Uta webmail
Electronic exam service
Examination results